Back HIV/Hepatitis Coinfection

Coinfection

Ribavirin Helps Early Hepatitis C Treatment in People with HIV

Adding ribavirin to pegylated interferon increases the likelihood of a cure for early hepatitis C virus (HCV) infection in people with HIV, according to study findings published in the May 2, 2012, advance online edition of AIDS.alt

Read more:

Liver Fibrosis Tests Predict Mortality in HIV/HCV Coinfected Women

More advanced liver fibrosis, as diagnosed by 2 non-invasive biomarker tests, is associated with a higher risk of death for HIV positive women coinfected with hepatitis C virus (HCV), according to a report in the March 13, 2012, issue of AIDS.alt

Read more:

CROI 2012: Long-term Tenofovir Promotes HBsAg Decline in HIV/HBV Coinfected People

Hepatitis B surface antigen (HBsAg) levels declined steadily in HIV/HBV coinfected patients treated with tenofovir for up to 8 years, especially those with rising CD4 T-cell counts, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this month in Seattle.alt

Read more:

CROI 2012: HIV Treatment May Reduce Mother-to-Child Hepatitis C Transmission

Effective antiretroviral therapy (ART) for HIV and maintaining a high CD4 T-cell count may decrease the risk of hepatitis C virus (HCV) transmission from HIV/HCV coinfected mothers to their babies, according to study findings presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this month in Seattle.alt

Read more:

Interferon-Based Therapy Reduces Liver Fibrosis Progression in HIV/HCV Coinfected Patients

Interferon-based treatment for chronic hepatitis C helps slow liver disease progression among HIV/HCV coinfected patients as it does for people with hepatitis C alone, according to study findings reported in the January 2012 Journal of Hepatology.

Read more:

CROI 2012: Detectable HIV Raises Risk of Incomplete Hepatitis B Suppression

HIV/HBV coinfected people with detectable HIV viral load and higher baseline HBV viral load were less likely to completely suppress hepatitis B after a year on tenofovir (Viread), but CD4 cell count did not show an effect, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this month in Seattle.alt

Read more:

Experts Issue Provisional Guidance on New Hepatitis C Drugs for HIV/HCV Coinfected Patients

HIV and hepatitis C virus (HCV) experts have issued preliminary recommendations for the use of the new HCV protease inhibitors boceprevir (Victrelis) and telaprevir (Incivek) for HIV/HCV coinfected patients. Though not yet FDA-approved for this group, studies to date show that the drugs improve the likelihood of a cure for coinfected as well as HCV monoinfected people.

[Editors' note (2/27/12): the preliminary recommendations have been temporarily withdrawn and removed from the Clinical Infectious Disease advance publication web section due to new data that may influence the guidance]  alt

Read more:

CROI 2012: HIV Positive People Need Ribavirin for Optimal Treatment of Acute Hepatitis C

HIV positive people acutely infected with hepatitis C virus (HCV) genotypes 2 or 3 benefit from receiving weight-based ribavirin in addition to pegylated interferon, according to study findings presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this month in Seattle.alt

Read more:

HIV/HBV Coinfection Raises Risk of AIDS Progression and Death

Coinfection with hepatitis B virus (HBV) nearly doubled the risk of progression to AIDS or death among people recently infected with HIV, according to a study described in the December 5, 2011, advance online edition of the Journal of Infectious Diseases.

Read more: